AstraZeneca PLC (OTCMKTS:AZNCF) Sees Significant Decrease in Short Interest

AstraZeneca PLC (OTCMKTS:AZNCF) saw a significant drop in short interest in December. As of December 15th, there was short interest totalling 58,800 shares, a drop of 69.5% from the November 30th total of 192,900 shares. Based on an average daily trading volume, of 6,300 shares, the days-to-cover ratio is presently 9.3 days.

Institutional Trading of AstraZeneca

An institutional investor recently bought a new position in AstraZeneca stock. Eagle Bay Advisors LLC purchased a new position in AstraZeneca PLC (OTCMKTS:AZNCF) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 1,001 shares of the company’s stock, valued at approximately $156,000. Institutional investors and hedge funds own 40.87% of the company’s stock.

AstraZeneca Stock Down 0.2 %

OTCMKTS:AZNCF traded down $1.53 during trading hours on Thursday, hitting $131.12. 3,766 shares of the stock were exchanged, compared to its average volume of 2,723. AstraZeneca has a twelve month low of $118.16 and a twelve month high of $175.00. The company’s 50 day moving average is $136.01 and its two-hundred day moving average is $150.94.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.